Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

Pfizer’s Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma

Approximately 475 new cases of the disease are diagnosed in Scotland every year

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

- PMLiVE

Climate of Health: the prescription for survival

Addressing climate change as a health crisis

- PMLiVE

Answering some of Pharma’s big questions to drive brand strategies

By James Aird and Zoë van Helmond

Amiculum

- PMLiVE

Gilead and AI-focused Genesis partner to develop small molecule therapies

The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead

- PMLiVE

Merck and Daiichi Sankyo’s ADC candidate ifinatamab deruxtecan shows promise in SCLC

Approximately 70% of small cell lung cancer patients are diagnosed with extensive-stage disease

- PMLiVE

Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria

Detailed results from the confirmatory trial will be submitted to the FDA later this year

- PMLiVE

Supporting Mental Health on Suicide Prevention Day: Mednet’s Commitment to Changing the Narrative

As part of Suicide Prevention Day, we take a look at the different ways we can support our colleagues' mental health and wellbeing and change the narrative around suicide

Mednet

- PMLiVE

Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m

The companies will use Genetic Leap's AI platform to generate oligonucleotide drugs against targets selected by Lilly

- PMLiVE

GSK shares positive phase 3 results for long-acting biologic in severe asthma

Depemokimab is designed to allow for six-month dosing intervals for patients with the lung condition

regeneron headquarters

Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links